Images List Premium Download Classic

Monoclonal Antibody

Monoclonal Antibody-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW Compounds binding to jmjd6 with antifibrotic activity
Fondazione Irccs "istituto Nazionale Dei Tumori"
February 15, 2018 - N°20180044433

The present invention relates to the interaction between jmjd6 protein and collagen and to the possibility of inhibiting this interaction for the prevention and treatment of fibrosis and of tumor metastases. The invention further relates to a compound that is able to block the interaction between collagen and jmjd6 protein, in particular the invention relates to a new monoclonal antibody ...
NEW Anti-glucosaminidase passive immunization for staphylococcus aureus infections
University Of Rochester
February 15, 2018 - N°20180044406

The present invention is directed to a monoclonal antibody that binds specifically to a staphylococcus aureus glucosaminidase and inhibits in vivo growth of s. Aureus. Also disclosed are monoclonal antibody binding portions, recombinant or hybridoma cell lines, pharmaceutical compositions containing the monoclonal antibody or binding portions thereof, and methods of treating s. Aureus infection and osteomyelitis, and methods for introducing ...
NEW Anti-glucosaminidase passive immunization for staphylococcus aureus infections
University Of Rochester
February 15, 2018 - N°20180043021

The present invention is directed to a monoclonal antibody that binds specifically to a staphylococcus aureus glucosaminidase and inhibits in vivo growth of s. Aureus. Also disclosed are monoclonal antibody binding portions, recombinant or hybridoma cell lines, pharmaceutical compositions containing the monoclonal antibody or binding portions thereof, and methods of treating s. Aureus infection and osteomyelitis, and methods for introducing ...
Monoclonal Antibody Patent Pack
Download 139+ patent application PDFs
Monoclonal Antibody Patent Applications
Download 139+ Monoclonal Antibody-related PDFs
For professional research & prior art discovery
inventor
  • 139+ full patent PDF documents of Monoclonal Antibody-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments
Navigo Proteins Gmbh
February 01, 2018 - N°20180030140

The present invention relates novel binding molecules comprising a ubiquitin mutein (affilin®) and a monoclonal antibody or antibody fragment. The invention refers to bispecific and/or bivalent binding proteins or to a therapeutically or diagnostically active component. The invention further relates to the use of these binding proteins' medicine, preferably for use in the treatment of cancer or autoimmune ...
A novel anti-egfr monoclonal antibody, method of making, and use thereof
Shanghai Biomabs Pharmaceuticals Co., Ltd.
February 01, 2018 - N°20180030139

The present invention provides a method for producing an anti-egfr monoclonal antibody and the applications thereof. The method comprises the steps of: designing and synthesizing the light chain and heavy chain according to the codons preferred by chinese hamster, transfecting gs knockout host cells cho-cr-gs−/−, culturing cells using serum-free technology, isolating and purifying the antibody, and obtaining the ...
Compositions and methods for treating fatty tissue buildup
Mhs Care-innovation Llc
February 01, 2018 - N°20180030133

The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type ii diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain and a marked decrease in lipid synthesis and accumulation.
Monoclonal Antibody Patent Pack
Download 139+ patent application PDFs
Monoclonal Antibody Patent Applications
Download 139+ Monoclonal Antibody-related PDFs
For professional research & prior art discovery
inventor
  • 139+ full patent PDF documents of Monoclonal Antibody-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel egfr binding proteins
Navigo Proteins Gmbh
February 01, 2018 - N°20180030098

The present invention relates to new egfr binding molecules based on ubiquitin muteins (affilin®), preferably affilin molecules having a characteristic three amino acid residue motif. The invention further refers to egfr binding molecules that bind to different or non-overlapping epitopes than the anti-egfr monoclonal antibody cetuximab. The invention further relates to the use of these egfr binding proteins in ...
Compositions and methods for treating obesity and hyperphagia
Mhs Care-innovation Llc
February 01, 2018 - N°20180028618

The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as prader-willi syndrome, obesity, metabolic syndrome, type ii diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain, weight loss, and/or reduction in ...
Pcsk9 antibody, and pharmaceutical composition and use thereof
Ad Pharmaceutical Co., Inc.
January 25, 2018 - N°20180024131

The present invention belongs to the field of immunology and molecular biology, which relates to an anti-pcsk9 antibody, the pharmaceutical composition and method of use thereof. In particular, the present invention relates to the monoclonal antibody, which can bind pcsk9 specifically, block association of pcsk9 with ldlr, upregulate the amount of ldlr on cell surface, heighten the metabolism of ldl ...
Soluble mic neutralizing monoclonal antibody for treating cancer
University Of Washington Through Its Center For Commercialization
January 18, 2018 - N°20180016339

Described herein are compositions and methods relating to antibodies that bind soluble mic (smic), e. G. For the treatment of mic-positive cancers.
Antibodies specific for hyperphosphorylated tau and methods of use thereof
H. Lundbeck A/s
January 18, 2018 - N°20180016330

The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (phf) tau (ps396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of alzheimer's disease and other tauopathies.
Monoclonal antibody for the diagnosis, treatment and/or prevention of brain tumors and brain lesions
Consejo Superior De Investigaciones Cientificas (csic)
January 11, 2018 - N°20180011095

The invention relates to the use of the monoclonal antibody nilo1 for the diagnosis, treatment and/or prevention of brain tumors and lesions. Particularly, the invention relates to methods for the diagnosis of brain tumors and brain lesions in which cells marked with said antibody, or with immunologically active fragments thereof, are detected. The invention also relates to the use ...
Modulation of charge variants in a monoclonal antibody composition
Oncobiologics, Inc.
January 11, 2018 - N°20180009876

Combinations of different chromatography modalities with particularly refined conditions significantly reduce acid charge variants in a preparation of monoclonal antibodies. The process for reducing acid charge variants utilizes a combination of anion exchange and hydrophobic interaction chromatography, followed by cation exchange chromatography polishing, whereby the levels of acidic or basic charge species of the monoclonal antibodies may be modulated to ...
Monoclonal Antibody Patent Pack
Download 139+ patent application PDFs
Monoclonal Antibody Patent Applications
Download 139+ Monoclonal Antibody-related PDFs
For professional research & prior art discovery
inventor
  • 139+ full patent PDF documents of Monoclonal Antibody-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Cd33 specific chimeric antigen receptors
Intrexon Corporation
January 04, 2018 - N°20180002397

Provided herein are chimeric antigen receptors (cars) for cancer therapy, and more particularly, cars containing a scfv from a cd33 monoclonal antibody. Provided are immune effector cells containing such cars, and methods of treating proliferative disorders such as acute myeloid leukemia (aml), and relapsed or refractory aml.
Anti-hsp70 specific chimeric antigen receptors (cars) for cancer immunotherapy
Cellectis
January 04, 2018 - N°20180000914

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from an anti-hsp70 monoclonal antibody, conferring specific immunity against hsp70 positive cells. The engineered immune cells endowed with such cars are particularly ...
Membrane transporter napi2b (scl34a2) epitope for antibody therapy, antibodies directed thereto, and target ...
December 21, 2017 - N°20170362336

The present invention relates generally to the membrane transporter napi2b (slc34a2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The slc34a2 epitope peptide encompassing amino acids 312-340 of slc34a2 has been identified as an ovarian cancer epitope using the monoclonal antibody mx35. The invention also relates to the use of slc34a2 and ...
Use of binding molecule specifically binding to precursor of brain-derived neurotrophic factor
Shanghai Yile Biotechnology Co., Ltd.
December 21, 2017 - N°20170362313

Disclosed herein is use of a binding molecule which specifically binds to a precursor of brain-derived neurotrophic factor (probdnf). The binding molecule for probdnf, especially a monoclonal antibody against probdnf, can be used to prevent, mitigate or treat autoimmune diseases.
Monoclonal and oligoclonal anti-egfr antibodies for use in the treatment of tumors expressing predominantly high ...
Merrimack Pharmaceuticals, Inc.
December 14, 2017 - N°20170356049

Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-egfr monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.
Monoclonal antibody against kir2ds1
National University Corporation Hokkaido University
December 07, 2017 - N°20170350892

A monoclonal antibody to kir2ds1 or a fragment containing an antigen-binding region thereof has vl having an amino acid sequence of seq id no: 1 or an amino acid sequence having the same amino acid sequence as the amino acid sequence except that one or several amino acids are conservatively substituted as cdr1, having an amino acid sequence of seq ...
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
Alexion Pharmaceuticals, Inc.
December 07, 2017 - N°20170349652

Eculizumab, a humanized monoclonal antibody against c5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (pnh). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center ...
Novel anti-cd38 antibodies for the treatment of cancer
Sanofi
November 30, 2017 - N°20170343550

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to cd38, are capable of killing cd3830 cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (adcc), and/or complement-dependent cytotoxicity (cdc). Said antibodies and fragments thereof may be used in the treatment of tumors that express cd38 protein, such as multiple myeloma, chronic ...
Loading